Stocklytics Platform
Asset logo for symbol TERN
Terns Pharmaceuticals
TERN48
$6.55arrow_drop_down3.39%-$0.23
Asset logo for symbol TERN
TERN48

$6.55

arrow_drop_down3.39%

Performance History

Chart placeholder
Key Stats
Open$6.81
Prev. Close$6.78
EPS-1.32
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range6.45
6.95
52 Week Range3.26
11.40
Ratios
Revenue-
EBITDA Margin %-
EPS-1.32

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Terns Pharmaceuticals (TERN)

Terns Pharmaceuticals, Inc. (TERN) is a biopharmaceutical company focused on discovering and developing innovative therapies to treat liver diseases and cancer. The company's mission is to improve the lives of patients suffering from these debilitating conditions. TERN stock price history shows the company's growth and success over the years.
Terns Pharmaceuticals, Inc. is committed to providing high-quality healthcare solutions for patients in need. The company's dedication to research and development has led to the development of numerous novel drug candidates, which are currently in various stages of clinical trials. With its strong portfolio of drug candidates, TERN is well-positioned to address the significant unmet medical needs in liver diseases and cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Headquarters
Foster City
Employees
46
Exchange
NASDAQ
add Terns Pharmaceuticals to watchlist

Keep an eye on Terns Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the 52-week high and low for Terns Pharmaceuticals (TERN)?

For Terns Pharmaceuticals (TERN), the 52-week high is $11.4, which is 74.05% from the current price. The 52-week low is $3.26, the current price is 100.92% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

What is Terns Pharmaceuticals's (TERN) price per share?

The current price per share for Terns Pharmaceuticals (TERN) is $6.55. The stock has seen a price change of -$0.23 recently, indicating a -3.39% change. This reflects the stock's recent market performance and investor sentiment.
help

Is Terns Pharmaceuticals (TERN) a growth stock?

Terns Pharmaceuticals (TERN) has shown an average price growth of -3.55% over the past three years. It has received a score of 61 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Terns Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Terns Pharmaceuticals (TERN) stock price performance year to date (YTD)?

As of the latest data, Terns Pharmaceuticals (TERN) has a year-to-date price change of 1.08%. Over the past month, the stock has experienced a price change of -14.04%. Over the last three months, the change has been -2.53%. Over the past six months, the figure is 11.21%.
help

Is Terns Pharmaceuticals (TERN) a profitable company?

Terns Pharmaceuticals (TERN) has a net income of -$90.21M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$102.56M. Furthermore, the EBITDA is -$107.91M.
help

What is the market capitalization of Terns Pharmaceuticals (TERN)?

Terns Pharmaceuticals (TERN) has a market capitalization of $553.06M. The average daily trading volume is 6.56, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level